A study by Deguise et al. reported that 37.5% of patients with primarily SMA types 1 and 2 and an average age of 3.8 years had an increased risk of developing dyslipidemia, and there was evidence of hepatic steatosis in their pathological specimens. This evidence concerns the gene SMN1 and Hepatic steatosis.